Arrowhead seeks approval to begin RNAi therapy trial for obesity treatment

Arrowhead Pharmaceuticals has submitted an application to the New Zealand Medicines and Medical Devices Safety Authority seeking clearance to commence a Phase I/IIa trial of its investigational RNA interference (RNAi) therapy, ARO-ALK7, aimed at treating obesity.